Clinical trial
Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced…
NCT00424632 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00424632 |
|---|---|
| Title | Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors |
| Official title | A Phase 1, Open Label, Multi-Center, Accelerated Dose-Escalation, Pharmacokinetic And Pharmacodynamic Trial Of The Oral Single Agent Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors For Whom No Standard Therapy Is Available |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumors |
| Intervention type | Drug |
| Interventions | PF-03814735 |
| Enrollment | 57 |
| Start date | Nov 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Jan 19, 2007 |
| Last update posted | Jun 25, 2012 |
| Countries | Belgium, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: